CL2009001956A1 - Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer. - Google Patents

Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.

Info

Publication number
CL2009001956A1
CL2009001956A1 CL2009001956A CL2009001956A CL2009001956A1 CL 2009001956 A1 CL2009001956 A1 CL 2009001956A1 CL 2009001956 A CL2009001956 A CL 2009001956A CL 2009001956 A CL2009001956 A CL 2009001956A CL 2009001956 A1 CL2009001956 A1 CL 2009001956A1
Authority
CL
Chile
Prior art keywords
vitamin
composition
folic acid
disease
manufacturing
Prior art date
Application number
CL2009001956A
Other languages
English (en)
Inventor
Quiñones Luis
Maccioni Ricardo
Saavedra Ivan
Sandoval Victor
Sandoval Ricardo
Original Assignee
Neuroinnovation Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroinnovation Spa filed Critical Neuroinnovation Spa
Priority to CL2009001956A priority Critical patent/CL2009001956A1/es
Publication of CL2009001956A1 publication Critical patent/CL2009001956A1/es
Priority to PCT/CL2010/000043 priority patent/WO2011041920A2/es
Priority to GB1207939.8A priority patent/GB2487871B/en
Priority to US13/496,140 priority patent/US8784804B2/en
Priority to CA2776919A priority patent/CA2776919C/en
Priority to AU2010305251A priority patent/AU2010305251B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICIÓN NUTRACÉUTICA PODEROSA ANTIOXIDANTE Y NEUROPROTECTORA QUE CONSISTE EN LA MEZCLA DE EXTRACTO DE SHILAJIT ANDINO (250 A 500 MG) Y ÁCIDO FÓLICO (200 A 500 UG), JUNTO A PEQUEÑAS CANTIDADES DE VITAMINAS B6 (20 A 40 UG) Y B12 (4 A 8 UG) CON SUMIDAS POR DÍA. SE DIVULGA ADEMÁS EL MÉTODO DE FABRICACIÓN DE LA COMPOSICIÓN POR MEZCLA ALEATORIA DE SUS COMPONENTES.<br /> ESTA COMPOSICIÓN, SE ENCUENTRA EN FORMA DE LIOFILIZADO, CÁPSULAS, COMPRIMIDOS O GRAGEAS Y ES ÚTIL PARA LA PREVENCIÓN Y TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.<br /> LA COMPOSICIÓN ES APROPIADA PARA EL CONSUMO HUMANO DE MANERA DIRECTA POR VÍA ORAL, YA SEA EN FORMA SÓLIDA COMO POLVO O EN SUSPENSIÓN DEL EXTRACTO, COMO ADITIVO EN ALIMENTOS O COMO AGENTE NUTRACÉUTICO. PUEDE SER FORMULADA COMO UN AGENTE NUTRACÉUTICO INGREDIENTE DE BEBIDAS O COMO MEDICAMENTO JUNTO A EXCIPIENTES AUTORIZADOS.<br />  
CL2009001956A 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer. CL2009001956A1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CL2009001956A CL2009001956A1 (es) 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.
PCT/CL2010/000043 WO2011041920A2 (es) 2009-10-09 2010-10-08 Composición nutracéutica que comprende extracto de shilajit, ácido fólico, vitamina b12 y vitamina b6 y su uso para prevenir y/o tratar enfermedades neurodegenerativas y/o el deterioro cognitivo asociado al envejecimiento cerebral
GB1207939.8A GB2487871B (en) 2009-10-09 2010-10-08 Nutraceutical composition comprising extract of Andean shilajit, folic acid, vitamin B12 and vitamin B6
US13/496,140 US8784804B2 (en) 2009-10-09 2010-10-08 Nutraceutical composition that comprises extract of andean shilajit, for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral aging
CA2776919A CA2776919C (en) 2009-10-09 2010-10-08 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing
AU2010305251A AU2010305251B2 (en) 2009-10-09 2010-10-08 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin B12 and Vitamin B6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2009001956A CL2009001956A1 (es) 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.

Publications (1)

Publication Number Publication Date
CL2009001956A1 true CL2009001956A1 (es) 2010-06-04

Family

ID=43857199

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001956A CL2009001956A1 (es) 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.

Country Status (6)

Country Link
US (1) US8784804B2 (es)
AU (1) AU2010305251B2 (es)
CA (1) CA2776919C (es)
CL (1) CL2009001956A1 (es)
GB (1) GB2487871B (es)
WO (1) WO2011041920A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296555A1 (en) 2013-12-20 2016-10-13 Ramiro Moises VERGARA CAMPILLO Combination of pyridoxine, folic acid and magnesium ions for treating cancer
US20170295834A1 (en) * 2015-11-25 2017-10-19 Alexander LaCroix All-Natural Bitterness-Reducing Flavor System

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
US6440436B1 (en) * 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US6558712B1 (en) * 2001-09-21 2003-05-06 Natreon Inc. Delivery system for pharmaceutical, nutritional and cosmetic ingredients
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
US7250181B2 (en) * 2005-01-19 2007-07-31 Natreon, Inc. Polyherbal compositions and methods for treating viral infections

Also Published As

Publication number Publication date
US8784804B2 (en) 2014-07-22
CA2776919A1 (en) 2011-04-14
GB2487871A (en) 2012-08-08
WO2011041920A2 (es) 2011-04-14
WO2011041920A3 (es) 2011-06-03
WO2011041920A8 (es) 2012-04-12
GB2487871B (en) 2017-04-05
AU2010305251A1 (en) 2012-05-31
CA2776919C (en) 2015-07-14
US20120269794A1 (en) 2012-10-25
AU2010305251B2 (en) 2013-12-19
GB201207939D0 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
CO6551760A2 (es) Polco de rifaximina , proceso para prepararlo y composiciones de liberación controlada que contiene dicha rifaeimina útil para obtener un efecto de larga duración
MX352434B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
PE20121406A1 (es) Cepas de lactobacillus plantarum como agentes hipocolesterolemicos
ECSP11011491A (es) Formulación en lípidos estabilizada de un promotor de la apoptosis.
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
TN2015000135A1 (en) Modified release formulations for oprozomib
AR098653A1 (es) Composición útil para promover la fertilidad femenina, composición de combinación
WO2012049222A3 (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
MX2015015628A (es) Acido graso del aceite de bogol para uso en suplementos y composiciones de tratamiento y piensos para animales.
HRP20161447T1 (hr) Pripravak koji sadrži ekstrakt zelenog čaja i ekstrakt nara, namijenjen upotrebi u sprječavanju ili usporavanju napredovanja raka prostate
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
MX2011011860A (es) Composicion estimulante inmune que comprende un extracto de aronia sp. en combinacion con selenio y/o zinc.
AR080052A1 (es) Composiciones que comprenden productos de azucar cisteina, bebida, contenedor de bebida, metodo
CL2009001956A1 (es) Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.
CO6450623A2 (es) Parasiticidas sanguineos
PH12017500743A1 (en) Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
GB2530226A (en) Chewable tablet
BR112014001728A2 (pt) fórmulas compreendendo elementos altamente solúveis e vitaminas para a prevenção e melhoria da osteoporose
PH12017501949A1 (en) Amyloid � fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid � fibril formation
PH12016501553A1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
WO2010142007A8 (pt) Composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
GR1008706B (el) Σκονη σαπουνιου και μεθοδος παρασκευης της
AR076016A1 (es) Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria